Alcon Inc.
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other product… Read more
Alcon Inc. (2U3) - Net Assets
Latest net assets as of December 2025: €0.00 EUR
Based on the latest financial reports, Alcon Inc. (2U3) has net assets worth €0.00 EUR as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€31.55 Billion) and total liabilities (€31.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €0.00 |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 44.97 |
Alcon Inc. - Net Assets Trend (2021–2025)
This chart illustrates how Alcon Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alcon Inc. (2021–2025)
The table below shows the annual net assets of Alcon Inc. from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €0.00 | -- |
| 2024-12-31 | €21.55 Billion | +4.50% |
| 2023-12-31 | €20.62 Billion | +4.81% |
| 2022-12-31 | €19.68 Billion | +2.19% |
| 2021-12-31 | €19.26 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alcon Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €22.01 Billion | 100.00% |
| Total Equity | €22.01 Billion | 100.00% |
Alcon Inc. Competitors by Market Cap
The table below lists competitors of Alcon Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Microchip Technology Inc
NASDAQ:MCHP
|
$33.80 Billion |
|
Medline Inc. Class A Common Stock
NASDAQ:MDLN
|
$33.89 Billion |
|
Bank Rakyat
PINK:BKRKY
|
$33.93 Billion |
|
Nutrien Ltd
NYSE:NTR
|
$34.02 Billion |
|
Orix Corp Ads
NYSE:IX
|
$33.63 Billion |
|
Chunghwa Telecom Co Ltd
NYSE:CHT
|
$33.61 Billion |
|
Keurig Dr Pepper Inc
NASDAQ:KDP
|
$33.57 Billion |
|
Archer-Daniels-Midland Company
NYSE:ADM
|
$33.40 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alcon Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 21,553,000,000 to 22,014,000,000, a change of 461,000,000 (2.1%).
- Net income of 980,000,000 contributed positively to equity growth.
- Dividend payments of 166,000,000 reduced retained earnings.
- Share repurchases of 676,000,000 reduced equity.
- Other factors increased equity by 323,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €980.00 Million | +4.45% |
| Dividends Paid | €166.00 Million | -0.75% |
| Share Repurchases | €676.00 Million | -3.07% |
| Other Changes | €323.00 Million | +1.47% |
| Total Change | €- | 2.14% |
Book Value vs Market Value Analysis
This analysis compares Alcon Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.50x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.72x to 1.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €39.29 | €67.64 | x |
| 2022-12-31 | €40.15 | €67.64 | x |
| 2023-12-31 | €41.81 | €67.64 | x |
| 2024-12-31 | €43.58 | €67.64 | x |
| 2025-12-31 | €45.16 | €67.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alcon Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.42%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.43x
- Recent ROE (4.45%) is above the historical average (3.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 1.95% | 4.54% | 0.30x | 1.45x | €-1.55 Billion |
| 2022 | 1.70% | 3.84% | 0.30x | 1.48x | €-1.63 Billion |
| 2023 | 4.72% | 10.30% | 0.32x | 1.44x | €-1.09 Billion |
| 2024 | 4.72% | 10.27% | 0.33x | 1.41x | €-1.14 Billion |
| 2025 | 4.45% | 9.42% | 0.33x | 1.43x | €-1.22 Billion |
Industry Comparison
This section compares Alcon Inc.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $8,161,291,461
- Average return on equity (ROE) among peers: 5.35%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alcon Inc. (2U3) | €0.00 | 1.95% | N/A | $33.76 Billion |
| Modern Dental Group Limited (1MD) | $2.36 Billion | 15.30% | 0.55x | $193.75 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $479.33 Million |
| Shofu Inc. (69W) | $35.51 Billion | 8.83% | 0.23x | $216.48 Million |
| 7VG (7VG) | $176.36 Million | 14.92% | 1.12x | $684.88 Million |
| Bio-gate AG (BIG1) | $4.25 Million | -42.46% | 0.46x | $2.79 Million |
| Paul Hartmann AG (PHH2) | $690.37 Million | 10.65% | 0.81x | $783.58 Million |
| Sartorius AG VZO O.N. (SRT) | $497.08 Million | 9.76% | 1.56x | $6.27 Billion |
| Shandong Weigao Group Medical Polymer Company Limited (UK2) | $25.34 Billion | 8.16% | 0.37x | $1.26 Billion |